lanraplenib (GS-9876)

News alerts, weekly reports and conference planners

Company:

Gilead, Ignota Labs, Lakefront Biotherapeutics

Drug class:

SYK inhibitor

Related drugs:

FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	GS-9876 Sensitive: C2 – Inclusion Criteria GS-9876 Sensitive : C2	GS-9876 Sensitive: C2 – Inclusion Criteria GS-9876 Sensitive : C2
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	GS-9876 Sensitive: D – Preclinical GS-9876 Sensitive : D	GS-9876 Sensitive: D – Preclinical GS-9876 Sensitive : D

Associations
(2)